World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
109
Citations
44205
World Ranking
518
National Ranking
315

Medicine

D-Index
109
Citations
44377
World Ranking
5772
National Ranking
3102

Daniel R. Kuritzkes publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Daniel R. Kuritzkes sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 482 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Daniel R. Kuritzkes D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Daniel R. Kuritzkes sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 109 D-Index — 90th percentile

90% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Daniel R. Kuritzkes is affiliated with Brigham and Women's Hospital in the United States. Their research spans several fields, with a primary focus on Medicine and Immunology and Microbiology. Within these broad areas, they have contributed extensively to subfields including Infectious Diseases, Virology, Molecular Biology, Immunology, and Epidemiology.

The scientist has a strong research record in HIV and COVID-19 related studies. Their main topics of work include:

  • HIV Research and Treatment
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • COVID-19 Clinical Research Studies
  • HIV-related health complications and treatments
  • SARS-CoV-2 and COVID-19 Research
  • Immune Cell Function and Interaction

Frequent publication venues for their work include:

  • UNC Libraries
  • Clinical Infectious Diseases
  • JAIDS Journal of Acquired Immune Deficiency Syndromes
  • Open Forum Infectious Diseases
  • AIDS

They have collaborated regularly with several co-authors, including:

  • Jonathan Z. Li
  • Mathias Lichterfeld
  • Joseph J. Eron
  • Athe Tsibris
  • Roger Shapiro

Representative recent papers authored or co-authored by Daniel R. Kuritzkes include:

  • "SARS-CoV-2 viral load is associated with increased disease severity and mortality" (2020, Nature Communications)
  • "Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications" (2022, Clinical Pharmacology & Therapeutics)
  • "Determination of RNA structural diversity and its role in HIV-1 RNA splicing" (2020, Nature)
  • "Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis" (2021, AIDS)
  • "Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19" (2021, JAMA)

Daniel R. Kuritzkes has been recognized as a Member of the Association of American Physicians. This membership indicates engagement with a professional community in the medical field.

Best Publications

  • Update of the Drug Resistance Mutations in HIV-1.

    Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Huldrych F Gunthard

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

    Jacob P. Lalezari;Keith Henry;Mary O'Hearn;Julio S.G. Montaner

  • Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update

    Diane E. Bennett;Ricardo J. Camacho;Dan Otelea;Daniel R. Kuritzkes

  • SARS-CoV-2 viral load is associated with increased disease severity and mortality.

    Jesse Fajnzylber;James Regan;Kendyll Coxen;Heather Corry

  • Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel

    Martin S. Hirsch;Françoise Brun-Vézinet;Richard T. D'Aquila;Scott M. Hammer

  • HIV viral load markers in clinical practice

    M S Saag;M Holodniy;D R Kuritzkes;W A O'Brien

  • Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management

    M S Hirsch;B Conway;R T D'Aquila;V A Johnson

  • Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection

    Roy M. Gulick;Roy M. Gulick;Heather J. Ribaudo;Cecilia M. Shikuma;Stephanie Lustgarten

  • Workshop on HIV Infection and Aging: What Is Known and Future Research Directions

    Rita B. Effros;Courtney V. Fletcher;Kelly Gebo;Jeffrey B. Halter

  • Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

    Martin S. Hirsch;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

    Martin S. Hirsch;Huldrych F. Günthard;Jonathan M. Schapiro;Francoise Brun-Vezinet

  • Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

    Joseph J. Eron;Sharon L. Benoit;Joseph Jemsek;Rodger David MacArthur

  • Immunologic Responses Associated with 12 Weeks of Combination Antiretroviral Therapy Consisting of Zidovudine, Lamivudine, and Ritonavir: Results of AIDS Clinical Trials Group Protocol 315

    Michael Marcel Lederman;Elizabeth Connick;Alan Landay;Daniel R. Kuritzkes

  • Update of the Drug Resistance Mutations in HIV-1: 2005.

    Victoria A. Johnson;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases

    Timothy J. Henrich;Emily Hanhauser;Francisco M. Marty;Michael N. Sirignano

  • International AIDS Society global scientific strategy: towards an HIV cure 2016

    Steven G Deeks;Sharon R Lewin;Anna Laura Ross;Jintanat Ananworanich

  • Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group.

    A J Japour;D L Mayers;V A Johnson;D R Kuritzkes

  • HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.

    Robert W. Shafer;Soo-Yon Rhee;Deenan Pillay;Veronica Miller

  • Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis

    Jonathan Z. Li;Roger Paredes;Heather J. Ribaudo;Evguenia S. Svarovskaia

Frequent Co-Authors

Victoria A. Johnson
Victoria A. Johnson University of Alabama at Birmingham
Jonathan Z. Li
Jonathan Z. Li Brigham and Women's Hospital
Douglas D. Richman
Douglas D. Richman University of California, San Diego
Roy M. Gulick
Roy M. Gulick Cornell University
Alan L. Landay
Alan L. Landay The University of Texas Medical Branch at Galveston
Michael M. Lederman
Michael M. Lederman Case Western Reserve University
Utkan Demirci
Utkan Demirci Stanford University
John W. Mellors
John W. Mellors University of Pittsburgh
Steven G. Deeks
Steven G. Deeks University of California, San Francisco
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career paths. Many programs offer accelerated routes, especially for students transitioning into healthcare. For example, accelerated BSN programs for non nurses provide a fast track to becoming registered nurses, which can be a valuable foundation for immunology-related roles.

Entry-level options like easy LPN programs to get into allow students to start clinical work sooner, gaining essential hands-on experience. This practical exposure is beneficial when pursuing advanced immunology studies or related healthcare careers.

For professionals aiming to specialize further, understanding which nurse practitioner program is easiest to enroll in can help streamline advancement. Nurse practitioner degrees build critical skills needed in immunology-driven patient care and research.

Specifically, top PMHNP programs with best clinical placement rates offer excellent opportunities for specialization in psychiatric mental health nursing, which often intersects with immunological health in holistic patient treatment approaches.

Exploring these programs online provides flexibility while advancing your career in healthcare and immunology fields. Leveraging these pathways can enhance both education and employment prospects.

Best Scientists Citing Daniel R. Kuritzkes

Trending Scientists

Recently Published Articles